| Today’s Big NewsMar 18, 2024 |
| By Gabrielle Masson After nearly a decade as No. 1, Roche was finally knocked off our list’s top spot, sent spinning down the ladder by a whopping $30 billion from Merck & Co. |
|
|
|
By Fraiser Kansteiner The FDA on Monday gave a thumbs up to Lenmeldy as the first gene therapy in the U.S. for kids with certain types of metachromatic leukodystrophy (MLD). |
By Ben Adams Nonprofit and advocacy group the AIDS Healthcare Foundation has spent many years lining up its sights on Gilead and its alleged “price gouging” tactics for its HIV/AIDS meds, but now another ‘G’ is in the crosshairs: GSK. |
By Conor Hale Designed by Dean Kamen's Deka R&D and connected with Tidepool's artificial pancreas software, the upcoming twiist pump has received the go-ahead from the FDA. |
|
Wednesday, March 27, 2024 | 10am ET / 7am PTThere can be numerous challenges encountered during biopharmaceutical process development. Join usfor an important look at formulation development specifically. Featuring real-world examples, this insightful discussion will explore key challenges, as well as the latest techniques and solutions for effectively overcoming current obstacles. Register now. 
|
|
By Kevin Dunleavy Two months after GSK sold a significant chunk of its stake in Haleon, Pfizer is prepared to do the same with a larger sell-off, according to the consumer healthcare company. Pfizer is set to reduce its stake in Haleon from 32% to 24% by selling 630 million shares in a public offering. |
By Andrea Park Until more is known about long COVID—and until any treatments have been approved specifically for the illness—according to a new campaign from Moderna, the best offense is a good defense, in the form of regular coronavirus vaccines. |
By Nick Paul Taylor The biotech IPO class of 2024 could be getting another member. Contineum Therapeutics is the latest company to test the waters, filing paperwork to raise money for phase 2 clinical trials of its lead prospect and a Johnson & Johnson-partnered molecule. |
By Zoey Becker The funding should extend bluebird bio's cash runway through the first quarter of 2026 as it advances three gene therapy launches. Previously, the company expected its cash to run out by this year's second quarter. |
By Conor Hale The surgical robot developer Titan Medical has decided to combine itself with Conavi Medical, maker of imaging guidance tech for minimally invasive cardiovascular procedures. |
By Angus Liu After a quick FDA approval in a subset of endometrial cancer, GSK is back with more data for two Jemperli regimens—including one with a PARP drug—in hopes of reaching a broader patient population. And AstraZeneca, utilizing a similar immunotherapy strategy, has also come up with a rivaling update as it awaits an FDA decision. |
By Annalee Armstrong Ten days after asking Congress to fund women’s health research with $12 billion, President Joe Biden is doing what he can to boost investment via an executive order to expand and improve research on women’s health. |
By Nick Paul Taylor Verastem Oncology has shared a different spin on what its near-approval treatment for low-grade serous ovarian cancer (LGSOC) could mean for patients, publishing survey results that dig into the effects of the disease on mental and physical health. |
By Helen Floersh Tenaya Therapeutics’ gene therapy for an inherited heart condition that can cause sudden death appears to be effective in mice, new data show. |
Fierce podcasts Don’t miss an episode |
| In this episode of 'The Top Line,' Fierce Biotech Senior Editor Annalee Armstrong interviews Karen Correa, Ph.D., from Takeda, discussing the crucial need for pharmaceutical companies to prioritize diversity in clinical trials. |
|
|---|
|
|
|
Monday, April 22, 2024 | 10am ET / 7am PTExplore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
